Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Accurate Vitamin D Total Assay Is Fully Automated

By LabMedica International staff writers
Posted on 16 Feb 2011
A fully automated Vitamin D total assay is traceable to liquid chromatography-mass spectrometry (LC-MS/MS), considered the gold standard in vitamin D testing.

The most widely used indicator of vitamin D status is the measurement of the metabolite 25-hydroxy vitamin D in either serum or plasma. More...
Because circulating 25(OH) D can arise from hydroxylation of either vitamin D2 or D3, measurement of total 25(OH) D (both D2 and D3) is essential for accurate assessment of vitamin D status.

Siemens Healthcare Diagnostics (Deerfield, IL, USA) offers a fully automated total 25(OH) vitamin D assay (~100% D2 and D3) assay employing proprietary monoclonal antibodies with traceability to LC/MS/MS. Laboratories can now meet the increased demands of vitamin D testing by consolidating the testing on a fully automated, high-throughput immunoassay system.

Vitamin D deficiency is associated with rickets in children and osteomalacia in adults, and long-term insufficiency of calcium and vitamin D leads to osteoporosis. Recently, studies have linked vitamin D deficiency to several other disease states such as cancer, cardiovascular, diabetes, and autoimmune diseases

"As testing volumes continue to increase, laboratories need to feel confident they can meet that demand with an accurate, reliable Vitamin D assay," said David Hickey, CEO, chemistry, immunoassay, automation, and diagnostics IT business unit, Siemens Healthcare Diagnostics. "The Advia Centaur Vitamin D Total assay enables laboratories to have it all-precise, consistent results with a turnaround time in as little as 18 minutes."

Siemens Advia Centaur Vitamin D Total assay has been CE-marked for use on the Advia Centaur/XP Immunoassay Systems. The Advia Centaur Vitamin D total assay is not yet available for sale in the United States.

Related Links:
Siemens Healthcare Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Thyroid Test
Anti-Thyroid EIA Test
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.